No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects-Reference-Cited by-同舟云学术

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

Published:2018-09-07 Issue:1 Volume:59 Page:139-152
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Vourvahis Manoli¹,McFadyen Lynn²,Nepal Sunil³,Valluri Srinivas Rao⁴,Fang Annie⁵,Fate Gwendolyn D.⁶,Wood Linda S.⁷,Marshall Jean‐Claude⁷,Chan Phylinda L. S.²,Nedderman Angus⁸,Haynes Julian⁸,Savage Mark E.⁸,Clark Andrew⁹,Smith Kimberly Y.¹⁰,Heera Jayvant¹¹

Affiliation:

1. PfizerClinical Pharmacology New York NY USA

2. PfizerPharmacometrics Sandwich UK

3. PfizerBiostatistics Collegeville PA USA

4. PfizerBiostatistics New York NY USA

5. PfizerClinical Development New York NY USA

6. PfizerPharmacokinetics and Drug Metabolism Groton CT USA

7. PfizerClinical Pharmacogenomics Groton CT USA

8. York Bioanalytical Solutions Sandwich UK

9. ViiV Healthcare London UK

10. ViiV Healthcare Research Triangle Park NC USA

11. PfizerClinical Development Groton CT USA